A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(30 sites)

Germany

Helios Klinikum Bad Saarow, Bad Saarow

DRK Kliniken Berlin Köpenick, Berlin

Ev. Diakoniekrankenhaus, Bremen

Universitätsklinik Köln, Cologne

St. Johannes Hospital, Dortmund